Sanofi-Aventis

SNY-N

NYSE:SNY

50.85
0.10 (0.20%)
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales.
More at Wikipedia

Analysis and Opinions about SNY-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
December 18, 2019
A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
December 18, 2019
A French drug company that is starting to run. Th patent cliff has occurred and they have been busy bringing in new products. They also have a very profitable consumer health business. Yield 3.44% (Analysts’ price target is $54.17)
TOP PICK
TOP PICK
October 17, 2019
A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
October 17, 2019
A great global business. A bit boring, but not worries about a big drug coming off patent. He expects healthy dividend growth over time. (Analysts’ price target is $52.00)
PAST TOP PICK
PAST TOP PICK
August 14, 2019
(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
August 14, 2019
(A Top Pick Aug 14/18, Up 7%) One of the largest pharma companies in the world. Their major products are looking good and their product pipeline has lots of opportunities.
WEAK BUY
WEAK BUY
July 17, 2019
It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.
Show full opinionHide full opinion
It hasn't done much lately. Boring. Little volatility. They have a great vaccine business and some exposure to Africa. Slow growth, but you get a great dividend. A conservative play.
PAST TOP PICK
PAST TOP PICK
July 3, 2019
(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.
Show full opinionHide full opinion
(A Top Pick Jul 04/18, Up 13%) One of three drug stocks he still owns. He likes the product selection and bought into it when they had a few key drugs that were coming off patent and the stock price had dropped. He has confidence they will continue to add new profitable drugs.
HOLD
HOLD
May 22, 2019
A French multi-national pharma that he owns. They get research going and buy smaller companies. They only need one or two promising drugs to make out well. A good long term hold.
Show full opinionHide full opinion
A French multi-national pharma that he owns. They get research going and buy smaller companies. They only need one or two promising drugs to make out well. A good long term hold.
HOLD
HOLD
May 3, 2019
Large cap out of France. Diversified. Likes the biologic focus. Bring more of an emerging market focus. Won't shoot the lights out, but likes the stable dividend and the 7.5% EPS growth. Not paying a lot for it.
Show full opinionHide full opinion
Large cap out of France. Diversified. Likes the biologic focus. Bring more of an emerging market focus. Won't shoot the lights out, but likes the stable dividend and the 7.5% EPS growth. Not paying a lot for it.
PAST TOP PICK
PAST TOP PICK
November 8, 2018
(A Top Pick Nov 22/17, Up 5%) They had come off a patent cliff. Now earnings are doing better. The whole US healthcare area is looking good. This one sells at a lower multiple than North American ones.
Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
November 8, 2018
(A Top Pick Nov 22/17, Up 5%) They had come off a patent cliff. Now earnings are doing better. The whole US healthcare area is looking good. This one sells at a lower multiple than North American ones.
TOP PICK
TOP PICK
August 14, 2018

The best time to buy drug stocks is after they have faced a patent cliff. They have lots of cash but they have to find new drugs by research or buy buying. Sanofi has lost competitions to buy drugs because they won’t pay too much for them. The stock has been behaving better lately as some of the acquisitions have been doing well. He thinks this is a good time to buy. (Analysts’ price target is $48.25)

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
August 14, 2018

The best time to buy drug stocks is after they have faced a patent cliff. They have lots of cash but they have to find new drugs by research or buy buying. Sanofi has lost competitions to buy drugs because they won’t pay too much for them. The stock has been behaving better lately as some of the acquisitions have been doing well. He thinks this is a good time to buy. (Analysts’ price target is $48.25)

TOP PICK
TOP PICK
July 4, 2018

A French pharmaceutical company, who has been impacted by patent protection ending on some key products. They lost out on a couple of acquisitions, that the company felt was too expensive. He believes this is a long term hold that will pay off over time. Yield 4.4%. (Analysts’ price target is $46)

Show full opinionHide full opinion

A French pharmaceutical company, who has been impacted by patent protection ending on some key products. They lost out on a couple of acquisitions, that the company felt was too expensive. He believes this is a long term hold that will pay off over time. Yield 4.4%. (Analysts’ price target is $46)

PAST TOP PICK
PAST TOP PICK
April 19, 2018

(A Top Pick May 1/17, Down 12%) He is being patient with it as they buy companies that are patient with new drugs.

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
April 19, 2018

(A Top Pick May 1/17, Down 12%) He is being patient with it as they buy companies that are patient with new drugs.

COMMENT
COMMENT
December 28, 2017

A direct competitor of Novo-Nordisk (NVO-N) in one part of their business. Their franchise in multiple sclerosis and vaccine business is their big powerhouse, but overall, revenues only grew by 2% in the quarter, and they've seen a drop off in their diabetes cardiovascular unit, which is where the growth is. He prefers Novo-Nordisk.

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
December 28, 2017

A direct competitor of Novo-Nordisk (NVO-N) in one part of their business. Their franchise in multiple sclerosis and vaccine business is their big powerhouse, but overall, revenues only grew by 2% in the quarter, and they've seen a drop off in their diabetes cardiovascular unit, which is where the growth is. He prefers Novo-Nordisk.

TOP PICK
TOP PICK
November 22, 2017

An international health care company, mainly in rare diseases, MS, immunology and oncology. Has been growing both by acquisition and through drugs of its own. Earlier this year, they bought Boehringer Ingelheim’s consumer products division. The latest quarter was a little soft and the market has punished them. He doesn’t worry about quarter to quarter. They’ve developed some drugs with Regeneron. Their partnership is dissolving, but any drugs they’ve developed, will continue on. A good, long term investment. Dividend yield of 3.7%. (Analysts’ price target is $54.)

Show full opinionHide full opinion
Sanofi-Aventis (SNY-N)
November 22, 2017

An international health care company, mainly in rare diseases, MS, immunology and oncology. Has been growing both by acquisition and through drugs of its own. Earlier this year, they bought Boehringer Ingelheim’s consumer products division. The latest quarter was a little soft and the market has punished them. He doesn’t worry about quarter to quarter. They’ve developed some drugs with Regeneron. Their partnership is dissolving, but any drugs they’ve developed, will continue on. A good, long term investment. Dividend yield of 3.7%. (Analysts’ price target is $54.)

PAST TOP PICK
PAST TOP PICK
July 25, 2017

(Top Pick July 25/16, Up 18.67%) They faced a patent cliff. They invested in smaller companies. He thinks the outlook is quite good.

Show full opinionHide full opinion

(Top Pick July 25/16, Up 18.67%) They faced a patent cliff. They invested in smaller companies. He thinks the outlook is quite good.

TOP PICK
TOP PICK
May 1, 2017

The ADR trades in New York. He does well buying drug companies when out of favour. They all face patent cliffs from time to time. The made acquisitions of some promising new drugs. They have an exemplary balance sheet. People hated it because they were in France with an election pending. (Analysts’ target: $47.00).

Show full opinionHide full opinion

The ADR trades in New York. He does well buying drug companies when out of favour. They all face patent cliffs from time to time. The made acquisitions of some promising new drugs. They have an exemplary balance sheet. People hated it because they were in France with an election pending. (Analysts’ target: $47.00).

Showing 1 to 15 of 25 entries

Sanofi-Aventis(SNY-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 5

Stockchase rating for Sanofi-Aventis is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Sanofi-Aventis(SNY-N) Frequently Asked Questions

What is Sanofi-Aventis stock symbol?

Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N

Is Sanofi-Aventis a buy or a sell?

In the last year, 5 stock analysts published opinions about SNY-N. 3 analysts recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Sanofi-Aventis.

Is Sanofi-Aventis a good investment or a top pick?

Sanofi-Aventis was recommended as a Top Pick by Norman Levine on 2019-12-18. Read the latest stock experts ratings for Sanofi-Aventis.

Why is Sanofi-Aventis stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Sanofi-Aventis worth watching?

5 stock analysts on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.

What is Sanofi-Aventis stock price?

On 2020-02-21, Sanofi-Aventis (SNY-N) stock closed at a price of $50.85.